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Virus-like particles (VLPs) are created by the self-assembly of multiple copies of envelope and/or capsid proteins from many viruses,
mimicking the conformation of a native virus. Such noninfectious nanostructures are mainly used as antigen-presenting platforms, especially
in vaccine research; however, some of them recently were used as scaffolds in biotechnology to produce targeted nanoparticles for intracellular
delivery. This study demonstrates the creation of fusion VLPs using hepatitis B core protein-based system maintaining a fibronectin-binding
property from B. burgdorferi BBK32 protein, including the evidence of particles’ transmission to BHK-21 target cells via caveolae/rafts
endocythosis. These results make this construct to be an attractive model in development of HBc-based nanoparticles for cellular targeting
applications and highlights the fragment of B. burgdorferi BBK32 as a novel cellular uptake-promoting peptide.
From the Clinical Editor: This paper discusses the nanotechnology-based application of self-assembling viral-like peptides (VLP-s) for targeted
delivery using a hepatitis B core protein based system. Creating fusion VLPs may be an attractive model for cellular targeting applications.
© 2013 Elsevier Inc. All rights reserved.
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particles in the size range 1 – 1000 nm — aim to create new
generations of drug-delivery vehicles, contrast agents, and
diagnostic devices.1 One of the relevant potentials of the
nanomedicines is their intracellular targeting possibility. Effec-
tive intracellular drug delivery is important for therapeutic agents
that have speciﬁc molecular targets inside a cell as well as for
drugs that undergo extensive efﬂux from the cell by the efﬂux
transporters. Thus, the ability to penetrate inside cells bypassing
lysosomal degradation is one of the key problems in the rational
design of pharmaceutical nanocarriers.2 For this purpose, the
surface of nanocarriers could be modiﬁed by certain
internalizable ligands (e.g., folate, transferrin) or by cell-
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polyArginine.3 This approach is receiving increasing attention
over the last years because it is efﬁcient for a range of cell
types, and various endocytotic mechanisms can be engaged to
facilitate the internalization of a carrier.2
Virus-like particles (VLPs) is a broad group of nanocarrier
systems that exhibit great potential in biomedicine research,
including targeted drug delivery.4 VLPs are self-assembling
noninfectious supramolecular structures that have been pro-
duced from structural proteins of a wide variety of virus
families. The unique features of VLPs are proper dimensions
for nanoscale applications, size homogeneity, a large surface
area-to-mass ratio, a symmetric macromolecular organization,
biodegradability, biocompatibility and ease of production/
puriﬁcation.5 In addition, a number of targeting molecules
and peptides can be displayed in a biologically functional form
on their capsid surface using chemical or genetic means.1
However, the issues of potential toxicity, biodistribution,
clearance rates, stability, and immunogenicity are not fully
addressed for these novel molecular devices for in vivo
biomedical applications.s for intracellular targeting addressed by B. burgdorferi BBK32 protein
.2012.05.003
Figure 1. (A) Schematic presentation of the fusion HBc/BBK32 constructs used in this study. BBK32 fragments were inserted in MIR of HBc protein. Gray
boxes: HBc fragments.White boxes: BBK32 fragments. Abbreviations of grey color represents linkers (amino acids GS and SS), and amino acids, added due to
introduction of the BamHI restriction site (amino acids P and D). (B) Three-dimensional prediction of the HBc VLP and individual HBc protein chains. (C)
Three-dimensional prediction of the individual HBc protein chains carrying different fragments of the BBK32 protein. Predictions were performed on the basis
of the x-ray structure of the HBc, genotype A,7 by a comparative modeling program 3D-JIGSAW (http://bmm.cancerresearchuk.org/3djigsaw/)30 and presented
by Chimera software.31 Chains A (orange red) and D (cornflower blue) of the HBc asymmetric tetramer unit are presented, but B and C chains are omitted for
visual clarity. Three BBK32 protein insertions are shown by blue, green and red.
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which self-assembles to form ~35-nm particles that comprise the
virion nucleocapsid. Dimer clustering of two HBc monomers
produces spikes on the surface of the capsid, and the loop region
located on top of these spikes (residues 78 – 83) is the major
target of the humoral response, i.e., major immunodominant
region (MIR).6,7 Generally HBc-based VLPs have been used as
an epitope presentation system in vaccine design and antigen
presentation studies.8-11 On the other hand, the ability of HBc to
incorporate peptides of different origin may be useful in the
development of NPs for different application.12 For instance,
packaging of enzymatically active nuclease, green ﬂuorescent
protein, RNA, and siRNA into the interior of recombinant
hepatitis B virus capsids was demonstrated.13-16 Moreover, it
was proposed that the inner VLP lumen may be modulated by C
terminal domain modiﬁcations; the authentic arginine-rich Cterminal domain packages RNA but may be replaced, within
limits by heterologous moieties that could act as cargo or provide
speciﬁc functions.17 However, transport of such particles in
extracellular space and their uptake by different cells is of crucial
signiﬁcance for expression of their desired biological activity, so
that it is necessary to design the appropriate targeting structures
on the surface of VLPs to enhance cellular internalization.
Fibronectin (FN) is a common constituent of the extracellular
matrix with important functions such as structural support and
signaling for cell survival, migration, contractility, and
differentiation.18 FN is a large glycosylated mosaic protein
composed of multiple copies of three types of modules: FNI,
FNII, and FNIII. These modules comprise several functional
domains that mediate interactions with cell-surface receptors
(integrin-binding tripeptide, Arg-Gly-Asp [RGD] peptide), other
ECM components (e.g., two heparin-binding domains, the
Table 1
Oligonucleotide primers designed for ampliﬁcation of BBK32 gene fragments
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ﬁbrin-binding sites), and FN itself. FN is secreted by different cell
types as a disulﬁde-bonded, soluble inactive dimer that is
subsequently assembled into an insoluble ﬁbrillar network.19 FN
acts as a ligand for bacterial and viral adherence to host cells and
plays a role in modulating the cellular entry of retroviral vector
particles.20,21 In addition, a number of studies suggested an active
role of FN adsorption in cellular uptake of nonviral nanocarriers
(for review, see Adler et al.22
A large amount of bacterial FN-binding protein has been
identiﬁed so far; among them is BBK32, a 47 kDa surface-
exposed lipoprotein and FN-binding adhesin of Borrelia
burgdorferi (B. burgdorferi).23,24 BBK32 contains multiple
FN-binding motifs located to an extended intrinsically disor-
dered segment.25 It was shown that the region of BBK32
comprising amino acids 147 – 205 binds to the N-terminal FNI
and FNIII modules, but residues 120 – 147 of BBK32 protein are
considered similar to the FN-binding region of SfbI protein from
S. pyogenes that had been shown to bind to the GBD of FN.26-28
Here we present the construction of HBc-based chimeric
VLPs with FN-binding property by insertion of B. burgdorferi
BBK32 fragments into the MIR region of capsid. The evidence
of intracellular internalization of these VLPs into nonphagocytic
cells through caveolae-mediated endocytosis makes this con-
struct an attractive model in development of HBc-based NPs for
medically relevant cellular targeting applications and highlights
the 130 – 166 aa fragment of B. burgdorferi BBK32 as a novel
cellular uptake-promoting peptide.Methods
Construction of plasmids and prediction of structure of chimeric
HBc/BBK32 VLPs
The construction design of fusion VLPs in this study involved
the insertion of a foreign sequence into the MIR of HBc protein
(Figure 1, A). The cloning vector pHBc encoding the full-length
(amino acids 1–183) of HBc protein, subtype ayw, with inserted
BamHI restriction site at MIR was constructed by M. Mihailova
like those described in another study.29
Three-dimensional predictions of the reconstructed HBc
structures were performed on the basis of the x-ray structure of
the HBc, genotype A,7 by a comparative modeling program 3D-
JIGSAW (http://bmm.cancerresearchuk.org/3djigsaw/)30 and
presented by Chimera software (Figure 1, B, C).31
The fragments of BBK32 gene-encoding amino acids 130 to
166, 160 to 175, and 153 to 175 (BF130-166, BF160-175, and
BF153-175 constructs, respectively) were ampliﬁed by PCR
from B. burgdorferi sensu stricto isolate B31 DNA sample. The
primers used to amplify these segments of BBK32 are listed inTable 1. A linker of two amino acids (GS) was added to the N-
terminal end of the insert, and a serine (S) was added to the C-
terminal end of insert. (The exception was BF130-166 construct,
where both C-end serines were of BBK32 origin). BamHI
restriction site was incorporated into both ends of inserts; the ﬁnal
peptide sequences are shown in Figure 1, A. The ampliﬁcation
products were digested with BamHI restriction endonuclease
(Fermentas, Vilnius, Lithuania), puriﬁed using QIAEX II Gel
Extraction Kit (Qiagen, Hilden, Germany), ligated into the
linearized cloning vector, and competent E. coli RR1 (F- leuB6
proA2 thi-1 araC14 lacY1 galK2 xyl-5 mtl-1 rpsL20 (Strr)
glnV44 Δ(mcrC-mrr) cells were transformed with plasmid. The
recombinant plasmids were isolated from positive clones by
standard techniques, and correct constructs were veriﬁed by
sequencing analysis.
Expression and purification of recombinant VLPs
Recombinant proteins were expressed in E. coli strain K802 by
standard techniques and puriﬁed by the combination of ion
exchange chromatography (IEC) on Q-HP Sepharose (GE
Healthcare, Helsinki, Finland) and size-exclusion chromatography
(SEC) on Sepharose 4FF (GE Healthcare) column methods
(Supplementary Materials Sections S1 and S2). Protein samples
were analyzed on a SDS-PAGE gel and by western blotting with
mouse monoclonal anti-HBc 13C9 antibodies,32 as well as by
double radial immunodiffusion according to Ouchterlony using
polyclonal rabbit anti-HBc antibodies (Dako, Glostrup, Denmark).
Electron microscopy
The puriﬁed fusion VLPs in suspension were adsorbed on
carbon-formvar-coated copper grids and negatively stained with
1% uranyl acetate aqueous solution. The grids were examined
with a JEM-100C electron microscope (JEOL Ltd., Tokyo,
Japan) at an accelerating voltage of 100 kV.
Evaluation of the FN-binding activity by ligand affinity blot
For the qualitative dot blot assay chimeric HBc/BBK32 VLPs
were spotted onto the nitrocellulose membrane and probed with
FN from human plasma followed by incubation with anti-FN
antibodies (Supplementary Materials Section S3). As a control,
recombinant full-length (HBc) core particles expressed in E. coli
were used.
Quantitative FN-binding assays on microtiter wells
Microtiter wells were coated with puriﬁed recombinant
BF130-166 or HBc proteins and probed with increasing
concentrations (0-10 μg/mL) of FN from human plasma
followed by incubation with anti-FN antibodies. For experiments
analyzing the role of gelatin- and heparin- binding domains of
Figure 2. Expression, puriﬁcation and morphologic analysis of fusion HBc/
BBK32 VLPs. Fusion HBc/BBK32 proteins were expressed in E. coli cells
and puriﬁed by the combination of techniques. The expression levels of the
proteins of interest were similar; the purity of the isolated proteins according
to Coomassie blue staining of the SDS-PAGE gel was 95%. Spherical
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binding analyses were performed by incubating 0.5 μg/mL of
FN to immobilized BF130-166 and HBc proteins in the
presence of gelatin or heparin at four competitor/FN molar
ratios (0.0/1, 0.25/1, 0.5/1 and 1/1) (Supplementary Materials
Section S4).
Cellular entry assay
For the cellular entry assays, BF130-166 VLPs were added to
the medium of baby hamster kidney BHK-21 cells to ﬁnal
concentration 5 μg/mL, and cells were incubated under different
conditions, each experiment was repeated three times. (i) To
investigate time-dependent uptake, cells were incubated with
VLPs for 5, 15, 30, 45 and 60 minutes at 37°C. (ii) To study the
uptake in the presence of gelatin, cells were pretreated with
gelatin (5 μg/mL or 20 μg/mL) for 15 minutes and incubated
with VLPs in the presence of gelatin for 45 minutes at 37°C. (iii)
To study the effect of sodium azide treatment, cells were
incubated with VLPs in the presence of 100 mM sodium azide in
the medium for 45 minutes at 37°C. (iii) To study the effect of
chlorpromazine (5 μg/mL) and ﬁlipin (5 μg/mL) treatment, cells
were pretreated with drug for 30 minutes33 and incubated with
VLPs in the presence of drug for 45 minutes at 37°C.
After incubation supernatants were removed and the cells
were washed once with ice-cold PBS, twice with an ice-cold
mild acidic wash buffer to remove external particles. The
localization of VLPs and FN in cellular space was evaluated by
ﬂuorescent double immunostaining method (Supplementary
Materials Section S5). For comparison, HBc particles were
used. Samples were examined with a laser confocal ﬂuorescence
microscope Leica TCS SP2SE. As a negative control cells
incubated without VLPs were used.particles of uniform size were obtained from all three constructs. Construct
BF130-166 is shown as an example. (A) SDS-PAGE of protein samples,
Coomassie brilliant blue staining, (B) Western blot with mouse monoclonal
anti-HBc 13C9 antibodies. Lane 1: lysate of E. coli cells, lane 2: 0.5 M
Urea supernatant, lane 3: 0.5 M Urea cellular debris, lane 4: supernatant
after precipitation with ammonium sulfate at 10% saturation, lane 5:
precipitate after precipitation with ammonium sulfate at 10% saturation,
lane 6: protein fraction puriﬁed by IEC on Q-HP Sepharose, lane 7: protein
fraction puriﬁed by SEC on Sepharose 4FF column, lane M: prestained
protein molecular weight marker in kDa. (C, D, E): Negative-staining
electron microscopy images of the puriﬁed BF130-166 (C), BF160-175
(D) and BF 153-175 (E) protein. Scale bars (in white) are 50 nm as indicated.Results
Synthesis and purification of fusion VLPs
Three recombinant plasmids encoding different fusion HBc/
BBK32 proteins were successfully constructed according to the
sequencing analysis of plasmid DNA (data not shown). Figure 1,
C presents three-dimensional predictive reconstructions of the
chimeric HBc protein chains, which are exposing the appropriate
BBK32 fragments on the tips of the HBc spikes. The BBK32
structure 130-166 seems to be the most ﬂexible, because
predictions for the four HBc chains vary from the mostly α-
helical (chain D) to the β-sheet-forming (chains A, B, and C).
The 153-175 and 160-175 insertions are predicted as mostly α-
helice-forming for all four HBc chain variants.
Obtained plasmids were transformed into E. coli and
recombinant proteins were expressed. SDS-PAGE and western
blot analysis indicated the expression of soluble recombinant
proteins of expected molecular weight, the levels of expression
were sufﬁcient for the further puriﬁcation procedures (Figure 2,
A and 2, B). Expressed recombinant HBc/BBK32 proteins were
puriﬁed from E. coli; the purity of the isolated proteins according
to Coomassie blue staining of the SDS-PAGE gel was 95%
(Figure 2, A). The ﬁnal yields of the recombinant proteins variedbetween 5 mg and 8 mg per 1 g of E. coli cells (data not shown).
Further examination of these preparations by electron micros-
copy revealed the presence of well-assembled particles of similar
size (approximately 30 nm-35 nm) and shape for all three
constructs (Figure 2, C, D, E).FN-binding property of chimeric VLPs
It was proposed that incorporation of B. burgdorferi BBK32
protein peptides harboring a FN-binding property into the
hepatitis B core virus-like particles would allow us to create
VLPs with enhanced FN-binding activity. The FN-binding
property of obtained VLPs was evaluated by dot blot analysis by
Figure 3. FN-binding properties of fusion HBc/BBK32 VLPs. (A) Dot blot
analysis. Here, 1 μg of puriﬁed VLPs was dotted on nitrocellulose
membrane for ligand blotting with FN from human plasma. The VLPs
designation is as follows: BF130-166, fusion HBc VLPs including amino
acids 130 to 166 of B. burgdorferi BBK32 protein; HBc, recombinant
VLPs containing unmodiﬁed hepatitis B core protein; BF160-175 and
BF153-175, fusion HBc VLPs including amino acids 160 to 175 or 153 to
175 of B. burgdorferi BBK32 protein, respectively. Only the BF130-166
VLPs bind human FN efﬁciently. (B) Dose-dependent, saturable binding of
human FN to BF130-166 protein. Binding of FN to immobilized BF130-
166 protein and HBc protein was analyzed by ELISA, with bound FN
detected by anti FN antibodies. (C) Effects of gelatin and heparin on
BF130-166 – FN interactions. Binding of human FN to immobilized
BF130-166 protein in the presence of gelatin (gray bars) and heparin (black
bars) was analyzed by ELISA, at gelatin or heparin/FN molar ratios of 0/1,
0.25/1, 0.5/1 and 1/1. Bound FN was detected by anti-FN antibodies. Dose-
dependent inhibition of FN binding by gelatin was observed. As a negative
control of the ELISA assays, corresponding amounts of FN were added to
5% milk-blocked wells, which did not contain any other immobilized
protein. Values represent FN binding minus background readings for
negative control wells.
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length HBc VLPs were used as a control. The results show that
only BF130-166 VLPs have pronounced FN-binding activity
(Figure 3, A). Very slight FN-binding activity was detected for
the construct BF160-175. No FN-binding activity was detected
for BF153-175 construct and HBc VLPs. Reverse ligand afﬁnityblot, in which FN, collagen, gelatin, and BSA were spotted on
the membrane and probed with recombinant VLPs followed by
incubation with polyclonal rabbit anti-HBcAg antibody, dem-
onstrated similar results. No binding was observed for collagen/
gelatin or BSA (data not shown).
The ability of BF130-166 to bind FN was further evaluated by
quantitative ELISA. Saturable, dose-dependent binding of FN to
BF130-166 was observed (Figure 3, B). The binding of FN was
speciﬁc for BF130-166 as the results for the recombinant insert-
free HBc VLPs could not be considered as positive.
Binding of BF130-166 to GBD of FN
FN is a multifunctional molecule that interacts with a number
of ligands via several distinct structural and functional domains.
The BBK32 fragment of the BF130-166 construct contains
putative GBD-binding motif28; therefore we next examined the
potential role of this FN domain in BF130-166 interactions with
FN. For this reason, FN binding by immobilized BF130-166 was
examined by ELISA in the presence of increasing concentrations
of gelatin, a known ligand for GBD. In a parallel assay, the
adhesion of FN to immobilized BF130-166 was examined in the
presence of increasing concentrations of heparin targeted to
block the heparin-binding domains of FN. As shown in Figure 3,
C, dose-dependent inhibition of FN binding by gelatin was
observed. In contrast, the presence of heparin had no effect on
FN – BF130-166 binding activity. These results indicated
that recombinant BF130-166 VLPs interact with GBD of the
FN molecule.
Cell-permeability of fusion BF130-166 VLPs
Because clear and strong FN-binding properties were
observed only for the construct BF130-166, the possible
internalization of these VLPs into BHK-21 cells was further
studied by confocal laser scanning microscopy. Culture of BHK-
21 cells was inoculated by BF130-166 particles and the time
course of internalization of VLPs was studied over 60 minutes’
incubation time at 37°C. For comparison, HBc particles were
used. The localization of VLPs and FN in cellular space was
evaluated by ﬂuorescent double immunostaining method. Only
green ﬂuorescence (FN) was observed in mock treated cells, as
expected (Figure 4, Control).
In BF130-166 NP-treated cells, the VLPs appeared as nano-
sized ﬂuorescent dots (red) mostly associated with cellular
membranes after 5 minutes’ incubation time. These VLPs were
not removed from the cellular surface during the acid wash; thus
we can suggest that this may reﬂect the initial cellular
internalization stage. The staining pattern of VLPs was
associated with the FN ﬂuorescence (green); therefore, these
results suggested co-localization of VLPs with FN in the cell line
studied (Figure 4). Further analysis revealed enhancement of
intracellular red signal in cell samples at 15 minutes’ and 30
minutes’ incubation time. In these images VLP- positive staining
mostly accumulated into discrete foci resembled a typical
endosomal or lysosomal punctuate pattern (Figure 4, 15`, and
30`). Subsequently the TRITC ﬂuorescence signal became
reduced and more dispersed as the time of incubation increased;
only a few red ﬂuorescent dots were observed in cells after 60
Figure 4. Fusion BF130-166 VLPs transmission to BHK-21 cells assessed by
confocal microscopy. Culture of BHK-21 cells were inoculated by VLPs and
the uptake of VLPs is depicted after 5, 15, 30, 45, and 60 min incubation time
at 37°C following acid wash to remove external particles. Cells were stained
with polyclonal rabbit anti-HBc antibody followed by TRITC-conjugated
anti-rabbit IgG secondary antibody (red), and monoclonal anti-FN antibody
followed by FITC-conjugated antimouse secondary antibody (green) in
double immunostaining experiment. Cells’ nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI, blue). No signal was observed in mock-
treated cells (Control). No intracellular VLP-positive signal was observed for
HBc VLPs. Scale bars (in white) are 20 μm as indicated.
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results suggest a process of intracellular degradation of the NPs.
In contrast, we did not observe pronounced changes in the green
ﬂuorescence pattern in cells over time (Figure 4, Anti-FN,
images 5` - 60`). The intracellular localization of HBc VLPs was
not observed (Figure 4, HBc 30`).
Cellular uptake of BF130-166 particles is inhibited by gelatin
Given the separable nature of particle attachment and cell
entry, we wanted to explore the possible role of binding to FN in
the cellular uptake. For this purpose increasing concentrations of
gelatin (5 and 20 μg/mL) were added to BHK-21 cells 15
minutes prior to experiments and remained present during the
incubation with VLPs. The result shows a decrease of VLPs-
positive signal in cells pretreated with 5 μg/mL gelatin and an
absence of this staining in cells pretreated with 20 μg/mL gelatin
(Figure 5, Anti-HBcAg, +gel. 5μg/mL and +gel. 20μg/mL).
This observation conﬁrms that BF130-166 particles internalized
the cells after binding to GBD of FN and veriﬁes the speciﬁcity
of binding and uptake.
Mode of uptake of BF130-166 particles
Next, we carried out a series of investigations on the uptake
mechanism. Endocytosis can be inhibited with the depletion of
cellular energy resources. The BHK-21 cells were incubated with
BF130-166 in the presence of sodium azide, which inhibits
active transport processes. Results show that the level of
ﬂuorescent intensity in the cytosol was reduced dramatically
relative to cells cultured in standard conditions (Figure 5, Anti-
HBcAg, +NaN3). These results suggest that recombinant
BF130-166 particles were internalized by endocytosis.
Further to inhibit clathrin-mediated and caveolin-mediated
endocytosis, BHK-21 cells were treated with either 5 μg/mL
chlorpromazine or 5 μg/mL ﬁlipin for 30 minutes, respectively.
The results show that chlorpromazine treatment did not inhibit
the entry of BF130-166; this observation suggests the clathrin-
independent internalization. In contrast, ﬁlipin, a sterol-binding
agent that disrupts caveolae and caveolae-like structures, strongly
inhibit the entry of BF130-166, suggesting a ﬁlipin-sensitive
pathway (Figure 5, Anti-HBcAg, +Chlorprom. and +Filipin).
These observations provide evidence that FN-binding BF130-166
VLPs enter the cells via caveolae/raft-dependent endocytosis.Discussion
VLPs, including HBc-based NPs, are emerging nanocarrier
platforms that can be tailored at the genetic level. The surface
modiﬁcation of such particles with an appropriate peptide
molecule is one of the possible strategies to inﬂuence the ability
of the engineered VLPs to interact with cells and tissues at a
molecular level and mediate the uptake by mammalian cells. To
date, several studies have been performed aimed at developing
HBc-based chimeric VLPs that could serve as potential
nanovehicles to target various cells.16,34,35 In this study, we
tested the possibility of exploiting the B. burgdorferi FN-binding
Figure 5. Fusion BF130-166 VLPs are endocytosed following attachment
to FN. Culture of BHK-21 cells were inoculated by VLPs and the uptake
of VLPs is depicted after 45 min incubation time at 37°C following acid
wash to remove external particles. Cells were stained with polyclonal
rabbit anti-HBc antibody followed by TRITC-conjugated anti-rabbit IgG
secondary antibody (red), and monoclonal anti-FN antibody followed by
FITC-conjugated antimouse secondary antibody (green) in double
immunostaining experiment. Cells’ nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI, blue). No signal was observed in
mock-treated cells (Control). Pronounced red signal was observed in
cells incubated with BF130-166 VLPs (45'). Similar signal was detected in
cells pretreated with 5 μg/mL chlorpromazine and incubated with BF130-
166 VLPs in the presence of chlorpromazine (+Chlorprom.) Intracellular
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FN-targeting system with subsequent transduction of target cells.
For this purpose, three fragments of B. burgdorferi FN-
binding protein BBK32 were inserted in MIR of the HBc protein:
amino acids 130 to 166, 160 to 175, and 153 to 175 (BF130-166,
BF160-175, and BF153-175 constructs, respectively), and fusion
proteins as VLPs were expressed in E. coli cells. HBc fusion
proteins often maintain the self-assembling ability and display
inserted foreign epitopes on the tips of particle spikes if they are
inserted into the MIR.6 However, folding and capsid formations
of the chimeric proteins are not always achieved easily, and the
insert size and composition often are limitation factors in this
process due to the conformational stress. Earlier it was shown
that failure of some chimeric proteins to assemble into VLPs
could be explained by the length of the insert; 120 amino acids
are usually accepted as a maximum. On the other hand, Kratz
et al36 reported successful insertion of the GFP protein (238
amino acids) in the HBc; thus the structural importance of
proper and independent folding of foreign sequences was
clearly demonstrated. The potential role of different characteristics
in the efﬁcient assembly of VLPs was addressed in numerous
studies, such as β-sheet forming properties, the distance between
the N and the C-terminus, and volume and hydrophobicity of the
amino acids of the insert. However, the nature of the insert makes it
often difﬁcult to manipulate, and the design of successful
constructs is still largely empirical. One of the most useful
strategies to inﬂuence the ﬂexibility of construct conformation is
the addition of linkers. The linker size and composition was shown
to have a strong effect on the VLPs’ assembling property.6,37 To
exploit these possibilities to overtake the assembly process, 41, 21,
and 28 amino acidswere inserted inHBc (BF130-166, BF160-175,
and BF153-175 constructs, respectively) including linkers. In
addition, three-dimensional predictions of the reconstructed HBc
structures were performed. The expression of all constructs in
E. coli resulted in stable, soluble proteins that were effectively
puriﬁed. Moreover, the electron microscopy data conﬁrmed that
all three HBc/BBK32 fusion proteins assembled properly into
symmetric particles indicating the successful design strategy
(Figure 3). The average size of the particles calculated from the
electron microscopy images was similar to the size of HBc
VLPs, indicating that small-sized inserts did not have a great
inﬂuence on the ﬁnal dimensions of chimeric VLPs. Interest-
ingly, recently the strategy of splitting the HBc protein inside
the insertion loop (SplitCore) was offered to overcome almost
accidental assembly process of chimeric VLPs.17
Another task of this study was to evaluate the FN-binding
properties of obtained fusion VLPs. Different BBK32 peptidesVLP-positive signal was decreased in cells pretreated with 5 μg/mL gelatin
and incubated with BF130-166 VLPs in the presence of gelatin for 45 min
at 37°C (+gel.5 μg/mL). Intracellular VLP-positive signal was absent in
cells pretreated with 20 μg/mL gelatin and incubated with BF130-166
VLPs in the presence of gelatin for 45 min at 37°C (+gel.20 μg/mL). The
red signal was markedly reduced in cells pretreated and incubated in the
presence of 100 mM sodium azide (+NaN3). The red signal was markedly
reduced in cells pretreated and incubated in the presence of 5 μg/mL
ﬁlipin (+ﬁlipin). Scale bars (in white) are 20 μm as indicated.
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regions.25-28 Our results show that only BF130-166 VLPs
demonstrated clear, strong FN-binding ability. Moreover, we
were able to show that this binding occurs via GBD of FN.
Unfortunately, the nature of inserts in BF160-175 and BF153-
175 constructs seems to be insufﬁcient to ensure stable ligand
binding. It could be explained by the manner of binding of this
BBK32 region to the N-terminal modules of FN that require an
antiparallel orientation of the binding partners with the peptide
forming additional β-strands at the edge of the triple-stranded β-
sheets of the two FNI modules (i.e., a “tandem-zipper”
mechanism).26 The 153-175 and 160-175 insertions were
predicted as α-helice-forming for all four possible chain variants;
therefore we could assume the lack of conformational compat-
ibility in FN binding for these VLPs (Figure 1). However,
induction of ordered aggregation of soluble FN and inhibition of
endothelial cell proliferation similar to that of anastellin were
shown for these BBK32 fragments, so there may be further
interest in these constructs in the future.27
Recently, retroviral binding to FN was associated with
increased infection of target cells and efﬁcient gene transfer.21,38
Therefore, we tested the possible intracellular entry of the
BF130-166 VLPs using BHK-21 as target cells. Indeed, the
results of confocal microscopy analysis clearly demonstrated
time-dependent particle uptake in BHK-21 cells. It was observed
that entry process started with the attachment of VLPs to the cell
surface followed by rapid internalization by energy dependent
endocytosis. Initial particle co-localization with FN supported
the idea that recombinant BF130-166 particles interact with FN
molecules in the cellular microenvironment. Furthermore we
were able to demonstrate the dose-dependant inhibition of the
intracellular uptake by gelatin pretreatment. These results
indicate that BF130-166 VLPs binding to the GBD of FN has
an active role in the internalization process.
The relatively fast uptake was similar to the process observed
for nonenveloped hepatitis C virus capsids in study by Katsarou
et al.39 Clathrin-mediated endocytosis was reported as an entry
pathway for these capsids as well as for HBc particles.39,40 In
contrast, binding to FN has been previously reported to result in
caveolae-dependent endocytosis of γ - retrovirus vectors.20
Noteworthy, α5β1 integrin, a cellular receptor required for FN
internalization, can be internalized by both clathrin-dependent
and caveolar endocytosis.41 In the present study we have tested
BF130-166 particles’ entry in the presence of chlorpromazine
and ﬁlipin, agents that block clathrin- and caveolae- dependent
uptake, respectively. The results show that inhibition of clathrin-
mediated endocytosis had no effect on the uptake, but the
disruption of membrane microdomains by the cholesterol-
chelating agent ﬁlipin completely opposes the internalization
of fusion VLPs. Accordingly, these data suggest that BF130-166
NP endocytosis in BHK 21 cells occurs via a non-clathrin-
mediated mechanism and likely involves caveolae/lipid rafts.
These ﬁndings may have signiﬁcant implications because certain
forms of caveolae-mediated endocytosis are thought to avoid the
degradative lysosomal compartment.22
In conclusion, we were able to obtain FN-binding HBc-based
VLPs with intracellular targeting properties. Although the
potential applications of these NPs in humans may be limiteddue to possible immunogenicity and the abundance of FN in
plasma, the evidence of particles’ fast and efﬁcient transmission
to target cells opens the possibility for using this system as an
intracellular delivery vector in vitro, as well as a model platform
for investigation of multifunctional NPs with targeted features.Acknowledgments
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